Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Cyclophosphamide 299 Cisplatin 298 Paclitaxel 258 Radiotherapy 255 Fluorouracil 234 Carboplatin 234 Docetaxel 231 Doxorubicin 216 Dexamethasone 166 Gemcitabine 156 Vincristine 147 Etoposide 136 Leucovorin 133 Capecitabine 129 Bevacizumab 129 Prednisone 125 Rituximab 118 Methotrexate 118 Cytarabine 110 Filgrastim 99 Trastuzumab 97 Oxaliplatin 96 pembrolizumab 83 Pemetrexed 73 Epirubicin 70 Tamoxifen 69 Drug Therapy 69 Irinotecan 66 Granulocyte Colony-Stimulating Factor 60 Nivolumab 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × lortalamine × Clear all

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡